Showing 1001-1010 of 1539 results for "".
- Biofrontera Unveils New Red-Light-Emitting Lamp for PDT on Actinic Keratoseshttps://practicaldermatology.com/news/biofronters-unveils-new-red-light-emitting-lamp-pdt-actinic-keratoses/2467140/Biofrontera Inc. announced the launch of the RhodoLED XL, a new red-light-emitting LED lamp approved by the US Food and Drug Administration (FDA) in combination with Ameluz (aminolevulinic acid hydrochloride) topical gel, 10% for photodynamic therapy of actinic keratoses of mild-to-moderate sever
- FDA Approves Gel for Axillary Hyperhidrosishttps://practicaldermatology.com/news/fda-approves-gel-axillary-hyperhidrosis/2467109/The US Food and Drug Administration (FDA) has approved a new prescription gel used to treat axillary hyperhidrosis (excessive underarm sweating) in adults and children 9 and older, manufacturer Botanix Pharmaceuticals announced. Sofdra (sofpironium) is the first chemical entity approved b
- Evaxion’s AI-Powered Cancer Vaccine Demonstrates High Response in Early Studyhttps://practicaldermatology.com/news/evaxions-ai-powered-cancer-vaccine-demonstrates-high-efficacy-in-early-study/2467073/Evaxion Biotech A/S, a firm specializing in AI-driven immunology vaccines, recently published data from its Phase 1 dose escalation study of the EVX-01 personalized cancer vaccine for metastatic melanoma showing almost 70% clinical response from patients. The study, published in the J
- Analysis: Few Dermatologists Share Sun Protection Advice on TikTokhttps://practicaldermatology.com/news/analysis-few-dermatologists-share-sun-protection-advice-tiktok/2467072/A new analysis in the Journal of Drugs in Dermatology shows a significant gap in the presence of board-certified dermatologists (BCDs) on TikTok, particularly concerning sun protection content. "Limited studies have analyzed sources of TikTok videos associated with sun safety and
- Neoadjuvant Ipilimumab and Nivolumab Therapy Improves Survival in Stage III Melanomahttps://practicaldermatology.com/news/neoadjuvant-ipilimumab-and-nivolumab-therapy-improves-survival-stage-iii-melanoma/2467064/New phase 3 study results from the NADINA study suggest that neoadjuvant (neoadj) therapy with ipilimumab (IPI) and nivolumab (NIVO) followed by response-driven adjuvant therapy was associated with increased event-free survival (EFS) in patients with macroscopic stage III melanoma. The re
- FDA Approves New Tralokinumab-ldrm Autoinjectorhttps://practicaldermatology.com/news/fda-approves-new-tralokinumab-ldrm-autoinjector/2467047/The US Food and Drug Administration (FDA) announced the approval of a new tralokinumab-ldrm 300-mg single-dose autoinjector for adult patients. Adbry® (LEO Pharma Inc.), a high-affinity fully human monoclonal antibody, is currently indicated in the US for the treatment of moderate-to-sever
- FDA Gives Green Light to InnoCare's Clinical Trial of TYK2 Inhibitor ICP-332 for ADhttps://practicaldermatology.com/news/fda-gives-green-light-innocares-clinical-trial-tyk2-inhibitor-icp-332-ad/2467004/InnoCare Pharma announced that the FDA has cleared its investigational new drug (IND) application for its novel TYK2 (Tyrosine Kinase 2) inhibitor, ICP-332. ICP-332 is a potent and selective TYK2 inhibitor. It achieved multiple efficacy endpoints in the China phase 2 study for the treatmen
- FDA Takes Key Step on Tapinarof for ADhttps://practicaldermatology.com/news/fda-takes-key-step-tapinarof-ad/2467002/The US Food and Drug Administration has accepted a supplemental new drug application for Dermavant’s VTAMA (tapinarof) following positive results of a Phase III clinical trial for the drug’s use on atopic dermatitis patients 2 and older, according to GlobalData. Tapinarof, an aryl hydrocar
- FDA-Cleared Fractional Laser for Hair Loss Now Availablehttps://practicaldermatology.com/news/fda-cleared-fractional-laser-hair-loss-now-available/2467000/The only US Food and Drug Administration-cleared fractional laser for safe, effective, and natural hair loss treatment is now available on the US market with the launch of FoLix from Lumenis Be. Ltd. Utilizing fractional laser and proprietary technology tailored for hair, FoLix offers res
- Tirbanibulin Approved for Actinic Keratosishttps://practicaldermatology.com/news/tirbanibulin-approved-actinic-keratosis/2466999/The U.S. Food and Drug Administration (FDA) has approved tirbanibulin (Klisyri, Almirall) for the treatment of actinic keratosis on an expanded area of the scalp and face, according to a news release from the manufacturer. The tirbanibulin ointment, 1% is a microtubule inhibitor with a f